Novartis gets global license to Portola's elinogrel; terminated
Portola Pharmaceuticals (developing new therapeutics for cardiovascular disease, inflammatory disease, and cancer) licensed Novartis exclusive worldwide rights to develop and commercialize its Phase II cardiovascular compound elinogrel (PRT060128).
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.